Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.
The Danish company’s latest deal covers glucose-sensitive insulin, which could avoid hypoglycaemia in type 2 diabetes patients.
A looming interim analysis could make Amryt a player in epidermolysis bullosa – and boost its deal-making ambitions.
If investors have visions of Luxturna-like prices they might need to blink and look again.
Epigenetics has so far failed to live up to the hype. But one UK player, Storm Therapeutics, still hopes to make a mark in a new field, RNA therapeutics.
Immunocore and Adaptimmune could shortly have a publicly listed rival.
Biohaven might soon be going up against Allergan in the acute migraine space, but the company believes size will not be a barrier to its success.
Can a device control a patient’s blood sugar based on bodyweight alone?